Cancer Shenzhen Yangli Pharmaceutical Technology describes new PARP-1 inhibitors July 12, 2024 Shenzhen Yangli Pharmaceutical Technology Co. Ltd. has patented poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer, ischemia and neurodegeneration.Read More
Cancer VB-15010, a potent and selective PARP-1 inhibitor and durable trapper, described April 12, 2024 Previous studies have shown that targeting poly(ADP-ribose) polymerase 1 (PARP-1) demonstrated promising activity for cancer treatment.Read More
